Stocktoria
Stoke Therapeutics, Inc. STOK
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-06-19
Chart by TradingView
4/9
Piotroski F — financial health
5.29
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M | — |
| Operating income | -$20.6M | -$101.4M | -$114.8M | -$104.4M | -$86.1M |
| Net income | -$6.9M | -$89.0M | -$104.7M | -$101.1M | -$85.8M |
| Operating cash flow | $45.6M | -$86.9M | -$81.1M | -$31.9M | -$66.9M |
| Free cash flow | $44.9M | -$87.1M | -$82.7M | -$35.8M | -$68.1M |
| Total assets | $418.4M | $271.6M | $228.3M | $256.1M | $238.9M |
| Total liabilities | $66.0M | $42.5M | $68.8M | $71.2M | $21.1M |
| Shareholders' equity | $352.5M | $229.0M | $159.6M | $184.8M | $217.8M |
| Ratios | |||||
| Operating margin | -11.2% | -277.3% | -1307.2% | -841.2% | — |
| Net margin | -3.7% | -243.4% | -1192.5% | -814.7% | — |
| FCF margin | 24.4% | -238.1% | -941.7% | -288.8% | — |
| Return on assets | -1.6% | -32.8% | -45.9% | -39.5% | -35.9% |
| Return on equity | -2.0% | -38.9% | -65.6% | -54.7% | -39.4% |
| Current ratio | 5.28 | 5.81 | 6.99 | 7.77 | 13.37 |
| Revenue growth | 404.5% | 316.3% | -29.2% | — | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 5.29 (safe)
- Working capital / assets 0.592
- Retained earnings / assets -1.189
- EBIT / assets -0.049
- Equity / liabilities 5.342
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001623526 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.